NLS Pharmaceutics Regains Compliance With Nasdaq Stockholders' Equity Requirement
NLS Pharmaceutics Regains Compliance With Nasdaq Stockholders' Equity Requirement
ZURICH, SWITZERLAND / ACCESSWIRE / January 25, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it received a notification letter from the Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000. The Company has now successfully resolved both outstanding Nasdaq compliance issues.
瑞士秀克黎世/ACCESSWIRE/2023年1月25日/致力於為罕見和複雜的中樞神經系統疾病患者發現和開發創新療法的瑞士臨床期生物製藥公司納斯達克製藥有限公司(納斯達克股票代碼：NLSP)(以下簡稱“公司”)今天宣佈，它已收到納斯達克股票市場有限責任公司(以下簡稱“納斯達克”)聽證會小組(“小組”)的一封通知信，通知公司公司已重新遵守納斯達克上市規則第5550(B)(1)條，該規則要求上市公司維持至少2500,000美元的股東權益。該公司現在已經成功解決了這兩個懸而未決的納斯達克合規問題。
As previously announced, on April 1, 2022, NLS was first notified by Nasdaq of its failure to comply with Nasdaq Listing Rule 5550(b)(1). As reported on November 14, 2022, following an appeal by NLS, the Panel granted the Company's request to continue its listing on Nasdaq and further requested that the Company demonstrate compliance with Listing Rule 5550(b)(1) no later than February 28, 2023.
如前所述，2022年4月1日，不良資產管理公司首次接到納斯達克的通知，稱其未能遵守納斯達克上市規則第5550(B)(1)條。據2022年11月14日報道，在NLS提出上訴後，陪審團批准了該公司繼續在納斯達克上市的請求，並進一步要求該公司至遲於2023年2月28日證明遵守了上市規則第5550(B)(1)條。
On January 24, 2023, the Panel confirmed the Company's compliance with the previously communicated conditions and determined that the Company regained compliance with Listing Rule 5550(b)(1). Accordingly, the Panel has determined to continue the listing of the Company's securities on Nasdaq and considers this matter closed.
2023年1月24日，專家小組確認該公司遵守了先前傳達的條件，並確定該公司重新遵守上市規則第5550(B)(1)條。因此，小組決定繼續將該公司的證券在納斯達克上市，並認為此事已經結束。
About NLS Pharmaceutics Ltd.
關於NLS製藥有限公司
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS製藥有限公司(納斯達克代碼：NLSP)是一家全球開發期生物製藥公司，與世界級合作夥伴和國際公認的科學家網絡合作，專注於為患有罕見和複雜的中樞神經系統疾病的患者發現和開發創新療法，這些患者的醫療需求尚未得到滿足。NLS總部設在瑞士，成立於2015年，由一支經驗豐富的管理團隊領導，該團隊在開發和商業化候選產品方面有著良好的記錄。欲瞭解更多資訊，請訪問。
For additional information:
有關更多資訊，請訪問：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
Marianne Lambertson(投資者和媒體)
NLS製藥有限公司。
+1 239.682.8500
郵箱：ml@nls-pharma.com
###
###
SOURCE: NLS Pharmaceutics AG
資料來源：NLS製藥公司